Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

This study tests the combination of palbociclib and afatinib — two targeted therapy drugs — in people with advanced squamous cell carcinoma of the esophagus or gastroesophageal junction that has progressed after prior treatment. **You may be eligible if...** - You have been diagnosed with advanced or inoperable squamous cell carcinoma of the esophagus or the junction where the esophagus meets the stomach - Your cancer has progressed after at least one prior chemotherapy regimen, including immunotherapy if not contraindicated - You are between 18 and 75 years old - You are in good general health (ECOG 0–1) with adequate organ function - You have at least one measurable tumor **You may NOT be eligible if...** - Your cancer is a different type (adenocarcinoma or mixed) - You have previously received CDK4/6 inhibitors or anti-EGFR drugs - You have a known allergy to the study drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.